Clinical trial · Interventional
The Multicentic Trial in Fertility-sparing Treatment and Ovarian Preservation Management for Early Endometrial Cancer
The Randomized Multicentic Prospective Controlled Trial in Fertility-sparing Treatment and Ovarian Preservation Management for Early Endometrial Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Through multicenter, prospective, randomized, controlled clinical studies comparing different treatment options (fertility-sparing surgery and ovarian preservation surgery and radical surgery)therapeutic efficacy, safety and quality of life of patients, exploration of the best strategies and risks for the treatment of early endometrial cancer, and promotion and application.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Endometrial Cancer | Malignant Endometrial Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| endometrial cancer radical surgery | Procedure | — | UNRESOLVED |
| fertility-sparing surgery | Procedure | — | UNRESOLVED |
| ovarian preservation surgery | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- radical surgery group
- description
- Endometrial cancer radical surgery to be administered in this arm.
- interventionNames
- Procedure: endometrial cancer radical surgery
- type
- EXPERIMENTAL
- label
- fertility preservation group
- description
- Fertility-sparing surgery to be administered in this arm.
- interventionNames
- Procedure: fertility-sparing surgery
- type
- EXPERIMENTAL
- label
- ovarian preservation group
- description
- Ovarian preservation surgery to be administered in this arm.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 21 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: 1. Premenopausal women, age ≤ 50 years 2. Surgical curettage / hysteroscopic pathology confirmed, endometrioid adenocarcinoma G1/G2 (including well-differentiated, high-medium and middle-differentiation); 3. Clinical consideration of IA (\<1/2 muscle infiltration); 4. First-time treatment 5. The subject (or his legal representative) must understand the nature of the study and sign an informed consent form. Exclusion Criteria: 1. At the same time participate in other clinical trials; 2. Can not tolerate surgery; 3. Ovarian suspicious metastasis; 4. Have a family history of ovarian cancer; 5. Incorporate other malignant tumors; 6. Preoperative CA125 abnormal persons
References
Publications (0)
Data not yet available